Business Wire - August 3, 2004
Dr. Malcolm Skolnick, CytoGenix, Chairman and CEO, states "We are keenly aware of the urgent need for this product. This accomplishment brings us one-step closer to obtaining FDA authorization to conduct clinical trials of our anti-herpes cream. Rarely does a week go by without receiving an email or telephone call from a herpes sufferer contacting us about the availability of this product. Our anti-herpes cream is designed to be effective against both labial (cold sores) and genital herpes."
Genital herpes is an epidemic in the US and other parts of the world reports the US Centers for Disease Control (CDC) "Genital herpes--herpes simplex virus type two (HSV-2)--is one of the most common sexually transmitted diseases in the United States, with as many as one million people becoming infected each year. While genital herpes continues to spread across all social, economic, racial and ethnic boundaries, prevalence of infection increased most dramatically in teens and young adults. The disease is potentially fatal in newborns and is a major cause of infant blindness. Herpetic infections increase the risk of contracting HIV and can be particularly severe in people with HIV infection. HSV-2 infection is more common in women (approximately one out of four women) than in men (almost one out of five)."
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis, anti-inflammatory topical creams and antibacterial compounds. The company owns a US patent for its core DNA expression technology and has over 40 international or US pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.
CONTACT: CytoGenix, Inc.
Juan Ferreira, 407-774-9949
SOURCE: CytoGenix, Inc.
040803
BW040804
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .